US 12588820

I'll research this specific patent number across the sources available to me.

Let me pull the claim language and litigation details more precisely.

US Patent 12,588,820 — Research Summary

Caveat up front: I could not retrieve the issued claim set verbatim for US 12,588,820. The authoritative text I have for this patent stops in the Detailed Description (mid-Section 1 on non-invasive glucose). Search results I found consistently referenced the sibling/specification-sharing patents (the ’475, ’790, ’484, ’304, ’455, ’533) rather than the ’820 itself. Claim characterizations below come from the patent's own SUMMARY section and should be treated as high-confidence but not verbatim claim text. I also found no Federal Circuit 2026 docket naming US 12,588,820 specifically — see the CAFC note at the end.

Bibliographic Data (per the authoritative patent text)

Continuation chain (from the patent's own CROSS-REFERENCE section): This application is a continuation of 18/891,970 (filed Sep. 20, 2024), which continues back through 18/438,144 (now US 12,193,790), 18/103,408 (US 11,896,346), 17/514,778 (US 11,564,577), 17/078,771 (US 11,160,455), 16/722,188 (US 10,820,807), 16/506,885 (US 10,517,484), and further parents rooted in the Dec. 17, 2013 PCT/US2013/075700 filing and Dec. 31, 2012 provisionals.

Classifications (representative): A61B5/00, A61B5/0002, A61B5/14532, A61B5/1455, A61B5/681/682, A61B5/7257 (Fourier transforms), G01J3/0218 (optical fibers in spectrometers), G16H40/63, G16H50/20, A61C19/04, H01S3/067 (fiber lasers).

Abstract (verbatim)

"A wearable device to measure a user's physiological parameters comprising one or more biosensors, as well as a light source comprising light emitting diodes, lenses for directing light towards tissue of the user comprising blood vessels, and a detection system receiving reflected tissue light. The physiological parameters, for example hypertension, are measured with a differential measurement. For example, the physiological parameters may be associated with pulse rate and blood flow. The output signal is associated with the physiological parameters, and artificial intelligence may be used in making decisions regarding the output signal. Signal-to-noise ratio of the output signal may be improved by synchronizing the detection system to the light source, increasing light intensity, and detecting a change. The wearable device is configured to determine that is being worn by the user and may be configured to communicate with a smartphone or tablet."

Independent Claims — Plain-Language Overview

Based on the SUMMARY section, the patent appears to have three independent claims (numbers not confirmed in my source material — treat "Claim 1 / Claim 2 / Claim 3" designations as illustrative):

1. Apparatus adapted to be worn by a user

• One or more biosensors placed on the user, measuring physiological parameters via a differential measurement — specifically pulse rate monitoring and blood flow measurement.
• A light source of multiple LEDs producing output optical light at one or more wavelengths.
• One or more lenses receiving that light and delivering it to tissue comprising skin.
• A detection system receiving reflected light and generating an output signal with a signal-to-noise ratio (SNR). It is (a) synchronized to the light source, (b) has multiple spatially separated detectors, and (c) has at least one analog-to-digital converter coupled to a detector.
• SNR is improved two ways: by increasing the LED light intensity from an initial level, and by comparing a "first signal" (LEDs off) with a "second signal" (at least one LED on) — i.e., dark/ambient subtraction.
• The apparatus is configured to determine, from the output signal, that it is being worn by the user.

2. Wearable device worn by a user

• A light source that can be on or off; when on, it generates output light.
• A lens directing at least part of that light toward the user's bodily tissue; and a detector.
• A processor configured to: (1) with the light on and the detector receiving reflected light, generate a first output signal with a first SNR; (2) with the light off and the detector receiving ambient light, generate a second output signal with a second SNR; (3) generate a third output signal from portions of the first and second output signals, having a third SNR greater than both the first and second SNRs, associated with a physiological parameter; and (4) determine from that third output signal that the device is being worn by the user.
• Note: as printed in the SUMMARY, this claim's transitional recitation is grammatically garbled ("...towards a bodily tissue of the user. a detector; and The processor is configured to..."). This may be an artifact of the text as fetched; the operative scope is as summarized above.

3. System for a device worn by a user

• A multi-LED light source producing output optical light; lens(es) directing light to bodily tissue.
• A detection system synchronized to the light source, receiving reflected light and generating an output signal with an SNR.
• SNR increased by raising LED intensity from an initial intensity.
• The detection system has spatially separated detectors and at least one ADC coupled to at least one detector.
• The output signal is associated with one or more physiological parameters and the system measures them when worn.
• The physiological parameters change in response to stretching of the user's hand, or movement of a finger or thumb — an explicit tie to wrist/hand-worn sensing.
• The device is configured to determine, at least partly from the output signal, that it is being worn by the user.

Common inventive thread across all three: LED-based optical sensing at skin, synchronized detection with spatially separated detectors + ADC, and a two-measurement (on/off) differential/dark-subtraction scheme to boost SNR — plus a wearer-detection function derived from the physiological output signal.

Litigation and Post-Grant Status

District court (per Google Patents litigation flag and docket search):

• Omni MedSci, Inc. v. [[Samsung Electronics Co.](/litigations/by-defendant/Samsung%20Electronics%20Co.) Ltd.](/litigations/by-plaintiff/Samsung%20Electronics%20Co.%20Ltd.) et al., No. 2:26-cv-00356 (E.D. Tex.) — the case flagged on the patent page; complaint filed ca. Jan. 2026 in Judge Rodney Gilstrap's court. Accused product families span smartwatches, rings, phones, and tablets.
• Related Omni MedSci filings in the same family/campaign include v. Fossil Group (2:26-cv-00470, E.D. Tex.), v. [Apple Inc.](/litigations/by-plaintiff/Apple%20Inc.) (7:26-cv-00226, W.D. Tex.), and v. Whoop, Inc. (1:25-cv-00140, D. Del.).
• Note: Omni MedSci's campaign pleadings I found assert the sibling ’475 (12,268,475), ’790 (12,193,790), ’484, ’304, ’455, ’533, and ’868 patents. I did not find a pleading that expressly asserts the ’820 itself — the ’820 is a very recent grant (March 31, 2026) and may be too new to have appeared in an assertion of record in my sources.

PTAB: Samsung (with Fossil, Oura, OnePlus) filed a coordinated wave of IPR/EPR/PGR petitions (e.g., IPR2025-01249 through 01253) against the family. Apple previously challenged the ’533 (IPR2019-00916, all challenged claims held unpatentable, affirmed by the Federal Circuit at 2022 WL 2062168) and the ’484 (IPR2021-00453). Law360 items dated May 2026 report the PTAB declining to run an IPR on an Omni MedSci wearable-device patent because a separate post-grant review would proceed, and a Director decision on the AIA effective-filing-date cutoff for the Omni MedSci patent.

Federal Circuit / CAFC 2026: I found no CAFC docket in 2026 listing US 12,588,820 as the patent on appeal. The relevant Federal Circuit activity is on related patents:

• Apple Inc., et al. v. Omni MedSci, Inc., No. 2023-1034 — "AFFIRMED-IN-PART, VACATED-IN-PART AND REMANDED" (Fed. Cir. June 21, 2024), addressing the ’484 patent's "identify/detect an object" limitations.
• Omni MedSci appeal of the ’484 remand decision, No. 2025-1646 (Fed. Cir.) — reported as pending.

Uncertainty: Because the ’820 issued only on March 31, 2026, any appeal or PTAB proceeding specifically about the ’820 would be at a very early stage. I cannot confirm from my sources that the ’820 is yet the subject of any CAFC appeal or PTAB trial. If you need that confirmed to a legal certainty, the authoritative check is the USPTO PatentCenter/PTAB portal and PACER for E.D. Tex. 2:26-cv-00356 — the patent number itself should be read literally as 12,588,820, and I did not substitute any similar number.